TR201505225A1 - A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. - Google Patents
A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. Download PDFInfo
- Publication number
- TR201505225A1 TR201505225A1 TR2015/05225A TR201505225A TR201505225A1 TR 201505225 A1 TR201505225 A1 TR 201505225A1 TR 2015/05225 A TR2015/05225 A TR 2015/05225A TR 201505225 A TR201505225 A TR 201505225A TR 201505225 A1 TR201505225 A1 TR 201505225A1
- Authority
- TR
- Turkey
- Prior art keywords
- weight
- pharmaceutical composition
- composition according
- tablets
- sulfate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 20
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 title claims abstract 5
- 229950004227 zaltoprofen Drugs 0.000 title claims abstract 5
- 208000012659 Joint disease Diseases 0.000 title claims abstract 3
- 208000015100 cartilage disease Diseases 0.000 title claims abstract 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract 3
- 229920002674 hyaluronan Polymers 0.000 claims abstract 3
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract 2
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 9
- 239000003826 tablet Substances 0.000 claims 9
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims 7
- 229940016409 methylsulfonylmethane Drugs 0.000 claims 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 2
- 229920002567 Chondroitin Polymers 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 229960002442 glucosamine Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000005323 carbonate salts Chemical class 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 239000007912 modified release tablet Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003735 xanthophylls Chemical class 0.000 claims 1
- 235000008210 xanthophylls Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Abstract
Mevcut buluş, eklem ve kıkırdak rahatsızlıkları, özellikle de osteoartrit ve romatoid artrit ile ilgili, enflamatuar ve ağrı semptomlarına karşı tedavi edici etkiye sahip, zaltoprofen, glukozamin sülfat, kondroitin sülfat ve hyaluronik asit içeren yeni bir farmasötik kompozisyon ile ilgilidir.The present invention relates to a novel pharmaceutical composition comprising zaltoprofen, glucosamine sulfate, chondroitin sulfate and hyaluronic acid having therapeutic effect against inflammatory and pain symptoms related to joint and cartilage disorders, particularly osteoarthritis and rheumatoid arthritis.
Claims (18)
1.A pharmaceutical composition comprising zaltoprofen, glucosamine, chondroitin and hyaluronic acid or their pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.
2.The pharmaceutical composition according to claim 1, wherein the amount of zaltoprofen is not more than 15 % by weight of the total composition.
3.The pharmaceutical composition according to claim 1, wherein the salt of glucosamine is glucosamine sulfate.
4.The pharmaceutical composition according to claim 1 or 3, wherein the amount of glucosamine sulfate is not more than 45 % by weight of the total composition.
5.The pharmaceutical composition according to claim 1, wherein the salt of chondroitin is chondroitin sulfate.
6.The pharmaceutical composition according to claim 1 or 5, wherein the amount of chondroitin sulfate is not more than 25 % by weight of the total composition.
7.The pharmaceutical composition according to claim 1, wherein the amount of hyaluronic acid is not more than 15 % by weight of the total composition.
8.The pharmaceutical composition according to claim 1, further comprising a dietary su pplement.
9.The pharmaceutical composition according to claim 8, wherein dietary supplement is selected from the group comprising methylsulfonylmethane (dimethyl sulfone), dimethyl sulfoxide, carbonate salts, probiotics, saccharides, vitamins, carotenoids, xanthophylls, minerals,electrolytes, preferably it is methylsulfonylmethane.
10)The pharmaceutical composition according to claim 9, wherein the amount of methylsulfonylmethane is not more than 15 % by weight of the total composition.
11)The pharmaceutical composition according to any of the preceding claims, wherein the excipient is selected from the group comprising buffering agents, stabilizers, binders, diluents, dispersing agents, Iubricants, glidants, disintegrants, plasticizers, preservatives, sweeteners, flavoring agents, coloring agents or mixtures thereof.
12) The pharmaceutical composition according to claim 1, wherein said composition is administering orally.
13) The pharmaceutical composition according to claim 12, wherein said composition is in
14) The pharmaceutical composition according to claim 13, wherein the solid dosage form is selected from the group comprising tablets, bilayer tablets, multilayer tablets, buccal tablets, sublingual tablets, tablet in tablets, in-Iay tablets, effervescent compositions, effervescent tablets, immediate release tablets, modified release tablets, ODT-ER (orally disintegrating tablets-extended release), film-coated tablets, orally disintegrating tablets, gastric disintegrating tablets, mini tablets; pills, capsules, hard or soft gelatin capsules, powders, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, dragees, sachets; orally administrable thin films, solutions or solids.
15) The pharmaceutical composition according to claim 14, wherein the solid dosage form is in the form of a tablet.
16) The pharmaceutical composition according to any of the preceding claims comprising; a Zaltoproten at 345% by weight, ) Glucosamin sulfate at 30-45% by weight, ) Chondroitin sulfate at 15-25% by weight, Hyaluranic asit at 5-1 5% by weight, Mannitol at 5-25% by weight, f) Crospovidon at 5-25% by weight, h) Magnesium stearate at O.1-5% by weight, i) Film coating (PVA based) at 1-5% by weight.
17) The pharmaceutical composition according to any of the preceding claims comprising; a) Zaltoprofen at 345% by weight, b) Glucosamin sulfate at 30-45% by weight, c) Chondroitin sulfate at 15-25% by weight, d) Hyaluranic asit at 5-1 5% by weight, e) Methylsulfonylmethane (MSM) at 545% by weight, f) Mannitol at 5-25% by weight, g) Crospovidon at 5-25% by weight, h) Talc at 0.1-5% by weight, i) Magnesium stearate at O.1-5% by weight, j) Film coating (PVA based) at 1-5% by weight.
18) The pharmaceutical composition according to any of the preceding claims, for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2015/05225A TR201505225A1 (en) | 2015-04-29 | 2015-04-29 | A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. |
| PCT/EP2016/059469 WO2016174124A1 (en) | 2015-04-29 | 2016-04-28 | Pharmaceutical composition comprising zaltoprofen, glucosamine, chondroitin, hyaluronic acid for joint and cartilage disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2015/05225A TR201505225A1 (en) | 2015-04-29 | 2015-04-29 | A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201505225A1 true TR201505225A1 (en) | 2016-11-21 |
Family
ID=55967224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2015/05225A TR201505225A1 (en) | 2015-04-29 | 2015-04-29 | A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR201505225A1 (en) |
| WO (1) | WO2016174124A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700003884A1 (en) * | 2017-01-16 | 2018-07-16 | Paolo Picciotti | PHARMACEUTICAL COMPOSITION BASED ON TRISODIC CITRATE FOR USE IN THE TREATMENT OF RHEUMATIC DISEASES. |
| KR102231289B1 (en) * | 2018-12-26 | 2021-03-23 | (주)휴온스 | High Content Chondroitin Sulfate Pharmaceutical Formulation and Manufacturing Method Thereof |
| IT202100017528A1 (en) * | 2021-07-02 | 2023-01-02 | Ezio Abbiati | IMPROVED COMPOSITION FOR THE TREATMENT OF CUTANEOUS, MUCOSAL AND CARTILAGE LESIONS IN GENERAL |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032188A1 (en) * | 1999-11-02 | 2001-05-10 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| US7803787B2 (en) * | 2002-10-16 | 2010-09-28 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage by transmucosal administration |
| WO2004034980A2 (en) * | 2002-10-16 | 2004-04-29 | Marcum Frank D | Treatment for traumatic synovitis and damaged articular cartilage |
| US20080227747A1 (en) | 2007-03-15 | 2008-09-18 | Tabbiner Philip | Composition and methods for treating or preventing degenerative joint and cardiovascular conditions |
| KR20130063183A (en) * | 2011-12-06 | 2013-06-14 | 대화제약 주식회사 | Novel crystalline s-zaltoprofen, method for preparing the same |
| US9295684B2 (en) * | 2012-06-07 | 2016-03-29 | Ming-Chen Lee | Cream composition enhancing skin absorption of glucosamine |
| CN103751767A (en) * | 2013-12-15 | 2014-04-30 | 青岛东海药业有限公司 | Medicament composition and application thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
-
2015
- 2015-04-29 TR TR2015/05225A patent/TR201505225A1/en unknown
-
2016
- 2016-04-28 WO PCT/EP2016/059469 patent/WO2016174124A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016174124A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201505225A1 (en) | A pharmaceutical composition comprising zaltoprofen for joint and cartilage disorders. | |
| US10130695B2 (en) | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | |
| JP2016540003A5 (en) | ||
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| JP2012031131A5 (en) | ||
| KR101923840B1 (en) | Composition and medicinal product for reducing body weight and body fat, and use of said product | |
| JP2012031147A5 (en) | ||
| NO20084065L (en) | Quick-release paracetamol tablets | |
| US20230293476A1 (en) | Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain | |
| HRP20190550T1 (en) | Formulations and methods of manufacturing formulations for use in colonic evacuation | |
| JPWO2012147986A1 (en) | Stable pharmaceutical composition | |
| TR201620151A2 (en) | ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN | |
| CN102137664B (en) | Pharmaceutical solid preparation having active ingredients separated by boundary therein | |
| BR102017011025A2 (en) | FORMULATION OF COMBINATION OF THREE ANTIVIRAL COMPOUNDS | |
| HRP20110089T1 (en) | Solid pharmaceutical composition comprising telithromycin | |
| WO2011080502A3 (en) | New pharmaceutical dosage form for the treatment of gastric acid-related disorders | |
| RU2007136963A (en) | COMPOSITION FOR ORAL USE WITH REGULATED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES | |
| JP2020530447A5 (en) | ||
| WO2016203018A1 (en) | Pharmaceutical compositions of prasugrel hydrobromide | |
| JP6206069B2 (en) | Solid preparation | |
| WO2018186650A3 (en) | Double composite tablet for oral administration containing tramadol and celecoxib | |
| TR201501970A2 (en) | Pharmaceutical combinations of dronedarone | |
| JP6296829B2 (en) | Granulated product containing hyaluronic acid, tablet produced using the granulated product, and swelling suppression method | |
| Samiyathuneesa et al. | Formulation and evaluation of atorvastatin floating tablet | |
| Shishehbori et al. | Formulation and in Vitro Evaluation of Ketoprofen Gastric Floating Matrix Tablet Based on Gas Formation. |